Bedrocan Initiates Domestic Production Operations

Live Plant Material Imported, First Crop Now Growing in Licensed Production Facility

TORONTO, March 11, 2015 /CNW/ - Bedrocan Cannabis Corp. (TSXV: BED) ("Bedrocan" or the "Company") announced that its recently licensed domestic production facility in the Greater Toronto Area is now operational. Live plant material consisting of genetic clones of Bedrocan's proprietary strains of medicinal cannabis, has been successfully imported from the Company's Dutch partner Bedrocan BV, and is now growing in the new facility's specially-designed grow rooms.

Bedrocan was issued separate import permits from both Health Canada and the Canadian Food Inspection Agency, allowing for the first-ever legal importation of live cannabis plants into Canada. The use of genetically-identical clones is a critical element of Bedrocan's pioneering standardization process. This process, which also includes a series of unique, proprietary production techniques, results in medicinal cannabis that provides patients with consistent levels of active ingredients (cannabinoids) in every batch, as is required for both prescription and over-the-counter (OTC) medicines. Bedrocan is the only company in the world capable of producing standardized full-bud medicinal cannabis and its alternate dispensed form, "Gran Flos", granulated full bud cannabis.

"We've achieved a major milestone with the launch of domestic production, and the transition to Phase II of our growth strategy," said Marc Wayne, President and CEO of Bedrocan. "The importation process went smoothly, our production technology is working flawlessly, and we're on track to harvest our first domestic crop for shipment to patients in Q2 2015."

About Bedrocan

Bedrocan and Bedrocan BV are focused on medicinal cannabis research and product innovation, and have been producing and supplying government-regulated medicinal cannabis for 13 years. Bedrocan's strains represent the world's only standardized (pharmaceutical grade), full-bud medicinal cannabis, and have been used by more than 20,000 patients in seven countries, including Canada. The Company is committed to clinical research, and has a commitment to quality with ISO 9001-rated production processes and product development, on an international scale. Bedrocan Cannabis Corp. trades on the TSX Venture Exchange under the symbol "BED". www.bedrocan.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Bedrocan Cannabis Corp.

Cam Battley, Bedrocan Cannabis Corp., [email protected], +1.905.864.5525, www.bedrocan.ca; Investor relations: Jennifer Wood, TMX Equicom, [email protected], +1.416.815.0700, ext. 226